Integral Health Asset Management, LLC
Reported holdings as of Q2 2026, from 27 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| REVOLUTION MEDICINES INC OPT | RVMD | $337.1M | 1,500,000 | +0.52pp | 14q | HELD | |
| INSMED INC | INSM | $170.6M | 1,600,000 | -4.99pp | 11q | +6.7%+$10.7M | |
| CYTOKINETICS INC | CYTK | $136.3M | 1,600,000 | -2.81pp | 26q | HELD | |
| CVS HEALTH CORP | CVS | $113.8M | 1,100,000 | +3.98pp | 7q | +633.3%+$98.3M | |
| EDGEWISE THERAPEUTICS INC | EWTX | $81.3M | 2,000,000 | +0.80pp | 8q | +25.0%+$16.3M | |
| VERA THERAPEUTICS INC | VERA | $75.1M | 1,750,000 | -0.11pp | 10q | +9.4%+$6.4M | |
| AXSOME THERAPEUTICS INC | AXSM | $73.4M | 300,000 | +2.62pp | 2q | +757.1%+$64.9M | |
| CARDINAL HEALTH INC | CAH | $71.3M | 300,000 | +0.09pp | 5q | +11.1%+$7.1M | |
| ROIVANT SCIENCES LTD | ROIV | $70.8M | 2,000,000 | +0.15pp | 6q | HELD | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $61.1M | 550,000 | -0.08pp | 5q | -8.3%-$5.6M | |
| EDWARDS LIFESCIENCES CORP | EW | $56.5M | 625,000 | +1.58pp | 6q | +267.6%+$41.2M | |
| ALIGNMENT HEALTHCARE INC | ALHC | $47.6M | 2,000,000 | -0.29pp | 7q | -22.3%-$13.7M | |
| MERCK & CO INC | MRK | $45.0M | 350,000 | -0.67pp | 3q | -17.6%-$9.6M | |
| NOVO-NORDISK A S OPT | NVO | $43.1M | 600,000 | - | new | NEW | |
| QUEST DIAGNOSTICS INC | DGX | $42.4M | 200,000 | +1.11pp | 5q | +233.3%+$29.7M | |
| UNIQURE NV | QURE | $41.5M | 900,000 | +0.93pp | 8q | HELD | |
| SCHOLAR ROCK HLDG CORP | SRRK | $41.2M | 750,000 | +0.45pp | 11q | +50.0%+$13.8M | |
| BOSTON SCIENTIFIC CORP | BSX | $38.4M | 900,000 | -0.13pp | 14q | +63.6%+$14.9M | |
| BRIGHTSPRING HEALTH SVCS INC | BTSG | $38.4M | 550,000 | -1.03pp | 8q | -56.0%-$48.8M | |
| ABBOTT LABORATORIES | ABT | $36.3M | 400,000 | - | new | NEW | |
| UNITEDHEALTH GROUP INC | UNH | $35.3M | 85,000 | - | new | NEW | |
| LIFESTANCE HEALTH GROUP INC | LFST | $32.1M | 3,000,000 | -0.04pp | 4q | -30.2%-$13.9M | |
| NOVARTIS AG | NVS | $31.3M | 200,000 | -0.59pp | 6q | -20.0%-$7.8M | |
| TANGO THERAPEUTICS INC | TNGX | $31.3M | 1,000,000 | +0.78pp | 3q | +122.2%+$17.2M | |
| TENET HEALTHCARE CORP | THC | $30.9M | 165,000 | - | new | NEW | |
| SPYRE THERAPEUTICS INC | SYRE | $28.9M | 325,000 | - | new | NEW | |
| DEFINIUM THERAPEUTICS INC | DFTX | $25.9M | 550,000 | +0.66pp | 2q | +37.5%+$7.1M | |
| NEUROCRINE BIOSCIENCES INC | NBIX | $25.3M | 150,000 | +0.05pp | 7q | HELD | |
| REGENERON PHARMACEUTICALS | REGN | $24.9M | 40,000 | -2.16pp | 5q | -52.9%-$28.1M | |
| IONIS PHARMACEUTICALS INC OPT | IONS | $23.8M | options only | +0.49pp | 2q | OPTIONS | |
| BIOGEN INC | BIIB | $21.6M | 100,000 | +0.33pp | 3q | +66.7%+$8.6M | |
| TRAVERE THERAPEUTICS INC | TVTX | $21.3M | 375,000 | - | new | NEW | |
| LANTHEUS HLDGS INC | LNTH | $21.1M | 190,000 | +0.38pp | 3q | +52.0%+$7.2M | |
| GLAUKOS CORP | GKOS | $21.0M | 150,000 | -0.07pp | 5q | -14.3%-$3.5M | |
| ORIC PHARMACEUTICALS INC | ORIC | $20.6M | 1,900,000 | -0.04pp | 5q | +35.7%+$5.4M | |
| BRIDGEBIO PHARMA INC | BBIO | $20.5M | 275,000 | -0.17pp | 2q | HELD | |
| VERTEX PHARMACEUTICALS INC | VRTX | $19.9M | 40,000 | -0.07pp | 2q | HELD | |
| ALUMIS INC | ALMS | $19.7M | 700,000 | -0.06pp | 2q | -12.5%-$2.8M | |
| ELEVANCE HEALTH INC FORMERLY | ELV | $19.3M | 50,000 | -0.29pp | 6q | -33.3%-$9.7M | |
| CENTENE CORP DEL | CNC | $19.3M | 300,000 | -0.26pp | 4q | -53.8%-$22.5M | |
| ERASCA INC | ERAS | $18.3M | 1,000,000 | +0.18pp | 2q | +42.9%+$5.5M | |
| ELI LILLY & CO | LLY | $18.0M | 15,000 | +0.05pp | 5q | HELD | |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | $16.3M | 200,000 | -0.26pp | 4q | -33.3%-$8.2M | |
| ENVISTA HOLDINGS CORPORATION | NVST | $15.8M | 600,000 | +0.20pp | 4q | +71.4%+$6.6M | |
| MEDTRONIC PLC | MDT | $15.6M | 200,000 | - | new | NEW | |
| WATERS CORP | WAT | $15.0M | 40,000 | - | new | NEW | |
| LIVANOVA PLC | LIVN | $14.8M | 180,000 | +0.13pp | 2q | +20.0%+$2.5M | |
| FORTE BIOSCIENCES INC | FBRX | $14.3M | 675,000 | +0.38pp | 2q | +350.0%+$11.2M | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $13.4M | 25,000 | -0.10pp | 2q | HELD | |
| PRAXIS PRECISION MEDICINES I | PRAX | $13.4M | 40,000 | -0.09pp | 3q | HELD | |
| ALTO NEUROSCIENCE INC | ANRO | $13.2M | 500,000 | -0.02pp | 7q | HELD | |
| MINERALYS THERAPEUTICS INC | MLYS | $12.1M | 450,000 | -1.14pp | 8q | -40.0%-$8.1M | |
| XENON PHARMACEUTICALS INC | XENE | $12.1M | 200,000 | -0.08pp | 2q | HELD | |
| ASCENDIS PHARMA A/S | ASND | $12.0M | 45,000 | - | new | NEW | |
| ACADIA HEALTHCARE COMPANY IN | ACHC | $11.8M | 400,000 | +0.24pp | 2q | +100.0%+$5.9M | |
| IRHYTHM HOLDINGS INC | IRTC | $10.7M | 90,000 | - | new | NEW | |
| BIOHAVEN LTD | BHVN | $10.4M | 700,000 | +0.01pp | 6q | -30.0%-$4.5M | |
| BEAM THERAPEUTICS INC | BEAM | $10.3M | 300,000 | +0.06pp | 5q | HELD | |
| INTEGRA LIFESCIENCES HLDGS C | IART | $9.9M | 550,000 | - | new | NEW | |
| GE HEALTHCARE TECHNOLOGIES I | GEHC | $9.6M | 150,000 | - | new | NEW | |
| REGENXBIO INC | RGNX | $9.6M | 800,000 | -0.22pp | 11q | -46.7%-$8.4M | |
| ABSCI CORPORATION | ABSI | $9.3M | 800,000 | - | new | NEW | |
| BRUKER CORP | BRKR | $9.0M | 150,000 | - | new | NEW | |
| CENCORA INC | COR | $8.5M | 30,000 | - | new | NEW | |
| COGENT BIOSCIENCES INC | COGT | $7.7M | 200,000 | -0.34pp | 2q | -42.9%-$5.8M | |
| ENLIVEN THERAPEUTICS INC | ELVN | $7.6M | 150,000 | - | new | NEW | |
| BIOAGE LABS INC | BIOA | $7.4M | 300,000 | - | new | NEW | |
| JAZZ PHARMACEUTICALS PLC | JAZZ | $7.2M | 30,000 | - | new | NEW | |
| SANA BIOTECHNOLOGY INC | SANA | $7.0M | 2,000,000 | -0.17pp | 10q | -37.5%-$4.2M | |
| INVENTIVA SA | IVA | $5.7M | 1,520,000 | +0.12pp | 2q | +280.0%+$4.2M | |
| PROTARA THERAPEUTICS INC | TARA | $5.7M | 1,500,000 | -0.21pp | 7q | -14.3%-$955.0K | |
| ALKERMES PLC | ALKS | $5.2M | 100,000 | - | new | NEW | |
| LB PHARMACEUTICALS INC | LBRX | $4.9M | 150,000 | +0.02pp | 4q | HELD | |
| KARDIGAN INC | KARD | $4.8M | 200,000 | - | new | NEW | |
| BIONTECH SE | BNTX | $4.7M | 50,000 | - | new | NEW | |
| INSPIRE MED SYS INC | INSP | $4.5M | 100,000 | - | new | NEW | |
| TREVI THERAPEUTICS INC | TRVI | $3.7M | 200,000 | - | new | NEW | |
| IDEAYA BIOSCIENCES INC | IDYA | $3.7M | 100,000 | - | new | NEW | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $3.7M | 100,000 | - | new | NEW | |
| SAVARA INC | SVRA | $3.7M | 600,000 | -0.01pp | 2q | HELD | |
| RELMADA THERAPEUTICS INC | RLMD | $3.5M | 500,000 | -0.01pp | 2q | +11.1%+$346.0K | |
| MOBIA MED INC | $3.4M | 250,000 | - | new | NEW | ||
| SIONNA THERAPEUTICS INC | SION | $3.3M | 75,000 | +0.03pp | 2q | +50.0%+$1.1M | |
| VERADERMICS INC | MANE | $3.1M | 25,000 | - | new | NEW | |
| INHIBIKASE THERAPEUTICS INC | IKT | $2.7M | 1,350,000 | flat | 3q | HELD | |
| REZOLUTE INC | RZLT | $2.6M | 500,000 | -0.19pp | 8q | -75.0%-$7.8M | |
| DENALI THERAPEUTICS INC | DNLI | $2.6M | 100,000 | - | new | NEW | |
| TENAX THERAPEUTICS INC | TENX | $2.4M | 167,000 | -0.03pp | 6q | HELD | |
| OLEMA PHARMACEUTICALS INC | OLMA | $1.3M | 100,000 | -0.06pp | 2q | -33.3%-$625.5K | |
| AURA BIOSCIENCES INC | AURA | $1.2M | 170,000 | - | new | NEW |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $1.9B | 73.3% |
| Healthcare Services | $269.4M | 10.6% |
| Medical Devices | $196.8M | 7.8% |
| Insurance | $121.5M | 4.8% |
| Wholesale & Distribution | $79.8M | 3.2% |
| Not classified | $8.1M | 0.3% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $2.5B | 90 | 29 | 23 | 21 | 25 | 47.0% | 45 |
| Q1 2026 | $2.1B | 86 | 28 | 29 | 17 | 26 | 51.8% | 45 |
| Q4 2025 | $2.0B | 84 | 23 | 34 | 19 | 13 | 43.1% | 48 |
| Q3 2025 | $1.5B | 74 | 19 | 27 | 19 | 16 | 46.3% | 45 |
| Q2 2025 | $1.1B | 71 | 18 | 24 | 16 | 27 | 46.1% | 45 |
| Q1 2025 | $939.8M | 80 | 28 | 18 | 27 | 29 | 46.8% | 45 |
| Q4 2024 | $1.2B | 81 | 33 | 28 | 13 | 18 | 40.7% | 45 |
| Q3 2024 | $888.7M | 66 | 31 | 13 | 15 | 34 | 50.8% | 45 |
| Q2 2024 | $1.1B | 69 | 22 | 29 | 11 | 30 | 45.7% | 45 |
| Q1 2024 | $1.1B | 77 | 28 | 27 | 16 | 18 | 34.0% | 45 |
| Q4 2023 | $734.3M | 67 | 31 | 14 | 20 | 29 | 35.5% | 45 |
| Q3 2023 | $722.3M | 65 | 24 | 24 | 14 | 32 | 36.1% | 45 |
| Q2 2023 | $807.6M | 73 | 33 | 24 | 12 | 31 | 37.2% | 42 |
| Q1 2023 | $496.4M | 71 | 31 | 21 | 18 | 21 | 31.0% | 39 |
| Q4 2022 | $476.4M | 61 | 29 | 20 | 11 | 33 | 34.5% | 44 |
| Q3 2022 | $514.8M | 65 | 22 | 22 | 21 | 22 | 33.8% | 45 |
| Q2 2022 | $486.2M | 65 | 15 | 40 | 9 | 21 | 40.7% | 34 |
| Q1 2022 | $384.3M | 71 | 18 | 39 | 11 | 18 | 35.8% | 42 |
| Q4 2021 | $361.4M | 71 | 22 | 23 | 17 | 21 | 38.3% | 33 |
| Q3 2021 | $347.9M | 70 | 25 | 18 | 22 | 26 | 35.8% | 43 |
| Q2 2021 | $363.2M | 71 | 25 | 21 | 19 | 23 | 35.6% | 61 |
| Q1 2021 | $350.0M | 69 | 31 | 19 | 18 | 19 | 37.4% | 40 |
| Q4 2020 | $336.2M | 57 | 18 | 16 | 19 | 33 | 39.7% | 47 |
| Q3 2020 | $327.0M | 72 | 32 | 19 | 19 | 20 | 35.7% | 47 |
| Q2 2020 | $333.9M | 60 | 29 | 13 | 13 | 20 | 34.0% | 45 |
| Q1 2020 | $227.0M | 51 | 31 | 12 | 7 | 30 | 39.8% | 45 |
| Q4 2019 | $256.8M | 50 | 0 | 0 | 0 | 0 | 42.1% | 44 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.